Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.
Vericel Corp (VCEL) insider Jonathan M. Hopper executed option-related transactions on 09/02/2025. Mr. Hopper exercised options with an $18 strike to acquire 10,000 shares and simultaneously sold 10,000 shares at $35.77 under an existing Rule 10b5-1 trading plan adopted May 30, 2025. After these transactions he beneficially owned 76,363 shares before the sale entry and 66,363 shares following the reported sale entry, reported as direct ownership. The reporting notes that some shares were acquired through the company’s 2015 Employee Stock Purchase Plan and that the underlying option grant (total right to buy 48,750 shares) vests in quarterly installments beginning May 11, 2020. The Form 4 was signed by an attorney-in-fact.
Form 144 filing for Vericel Corporation (VCEL) shows a planned sale of 10,000 common shares held by the reporting person through Fidelity Brokerage Services. The filing lists an approximate aggregate market value of $357,700 for the shares to be sold and indicates the shares represent part of an option granted on 02/11/2020 and acquired on 09/02/2025, with cash payment at exercise. The issuer's total shares outstanding are shown as 50,460,205, so the proposed block is a small fraction of the company. The filing also discloses a prior sale of 10,000 common shares by the same person on 06/02/2025 for $400,924. The notice affirms the signer does not possess undisclosed material adverse information.
Kevin F. McLaughlin, a director of Vericel Corporation (VCEL), exercised 7,000 stock options at an exercise price of $2.76 and immediately sold 7,000 common shares at $35.92 on 08/06/2025 pursuant to a Rule 10b5-1 trading plan adopted March 11, 2024.
After these transactions the filing reports beneficial ownership of 15,100 common shares. The filing also states the options originally granted on May 4, 2016 represented the right to purchase 15,000 shares and shows 0 derivative securities beneficially owned following the reported transactions.